Menthol In Neuropathy Trial (MINT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04276727|
Recruitment Status : Completed
First Posted : February 19, 2020
Last Update Posted : September 14, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Chemotherapy-induced Peripheral Neuropathy||Drug: MINT study IMP||Phase 2|
Modern cancer treatments, while more effective at prolonging life, are associated with some long lasting effects, especially nerve pain. This occurs in up to 90% of patients and 50% of patients still experience nerve pain a year after treatment. Not only is this distressing in itself but the investigators now understand that this treatment-related pain is exacerbating other pains, making cancer pain more difficult to control. The problem with managing nerve pain caused by treatment is that there is no predictable and effective treatment.
Our team has discovered that menthol cream or gel applied to the skin in the area of nerve pain can be effective. This trial seeks to provide better evidence of using this simple, cheap, non-toxic treatment. Participants will be given either menthol gel to the affected area or a placebo gel which smells, looks like and has the same texture as menthol but has no active drug. The gel will be applied twice a day for 6 weeks.
Participants will initially be assessed for pain and its impact on function, mood and quality of life and, if possible, will also have an fMRI scan immediately before starting menthol treatment and after 6 weeks of treatment. They will also have some assessments a further 6 weeks after treatment finishes. As part of impact on function assessment, participants will be asked to wear a physical activity monitor for a few days prior to each of the three main assessment points.
Our group has used special scans of the brain called fMRI to help identify if a treatment has real potential for patients. Sometimes, in early studies of a new treatment, patients can believe that the treatment has a real effect, but in fact it is a placebo effect. FMRI scans in this study will help to identify if menthol gel is having a true pain relieving effect, by comparing the patient's reports of pain with their scan findings. This will be very helpful in aiding the decision of how the research team conduct any future larger clinical trial.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||52 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Randomised, double-blind placebo controlled|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
|Masking Description:||Gel tubes will be supplied with similar labelling, identified by blinded drug pack numbers which can be linked to the treatment allocation if an emergency need arises. The menthol and placebo gels have a similar blue colour and both have a minty odour.|
|Official Title:||A Phase II RCT of Topical Menthol Gel Versus Placebo in the Treatment of Chemotherapy Induced Peripheral Neuropathic Pain|
|Actual Study Start Date :||November 4, 2019|
|Actual Primary Completion Date :||March 24, 2022|
|Actual Study Completion Date :||March 24, 2022|
Active Comparator: Menthol
Menthol gel to be applied twice a day for 6 weeks - toes to knees, fingertips to elbows, top and base of spine.
Drug: MINT study IMP
Application of gel for 6 weeks.
Placebo Comparator: Placebo
Placebo gel to be applied twice a day for 6 weeks - toes to knees, fingertips to elbows, top and base of spine.
Drug: MINT study IMP
Application of gel for 6 weeks.
- Reduction in CIPN symptoms [ Time Frame: 6 weeks ]A clinically significant reduction in pain (at least a 30% decrease in total BPI SF score as relates to the index neuropathic pain) between baseline and 6 weeks.
- Treatment effect on Chemotherapy Induced Peripheral Neuropathy [ Time Frame: 6 weeks ]Changes in EORTC QLQ (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires) CIPN-20 (severity of 20 symptoms rated on 4 point scale from Not at all to Very much)
- Treatment effect on quality of life functions [ Time Frame: 6 weeks ]Changes in EORTC QLC-c30 scores (30 symptoms on same scale as CIPN)
- Treatment effect on pain scores [ Time Frame: 6 weeks ]Changes in Brief Pain Inventory - Short Form scores (13 symptoms rated from 0 None to 10 Worst)
- Treatment effect on anxiety and depression [ Time Frame: 6 weeks (14 symptoms rated from 0 to 3 in severity) ]Changes in Hospital Anxiety and Depression Scale (HADS) scores
- Treatment effect on pain catastrophisation [ Time Frame: 6 weeks (13 questions rated from 0-4 in severity) ]Changes in Pain Catastrophising Scale (PCS) scores
- Treatment effect on side effects [ Time Frame: 6 weeks ]Changes in side effects (Yes/No to any SEs, description of SE to be given)
- Treatment effect on physical activity [ Time Frame: 6 weeks ]Changes in Actigraph data (measures of step counts, amount of moderate/vigorous activity and sleep times/efficiency)
- Perceived effects of IMP [ Time Frame: 6 weeks ]Changes in perceived effects questions (How long participant thinks treatment takes to take effect and how long it lasts for)
- Changes in Functional Magnetic Imaging data [ Time Frame: 6 weeks ]Changes in FMRI data pre and post treatment
- Post treatment changes in CIPN [ Time Frame: 12 weeks (from baseline) ]Changes in CIPN-20 scores (see secondary outcomes above for details of all questionnaire measures)
- Post treatment changes in quality of life measures [ Time Frame: 12 weeks (from baseline) ]Changes in QLQ-c30
- Post treatment changes in pain scores [ Time Frame: 12 weeks (from baseline) ]Changes in BPI-SF
- Post treatment changes in anxiety and depression [ Time Frame: 12 weeks (from baseline) ]Changes in HADS scores
- Post treatment changes in pain catastrophising [ Time Frame: 12 weeks (from baseline) ]Changes in PCS
- Post treatment changes in side effects [ Time Frame: 12 weeks (from baseline) ]Changes in Side effects
- Post treatment changes in physical activity [ Time Frame: 12 weeks (from baseline) ]Changes in Actigraph data
- Changes in sensory measures [ Time Frame: 6 weeks and 12 weeks (from baseline) ]Changes in QST data
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Patients have received any neurotoxic chemotherapy.
- Patients have experienced post treatment Chemotherapy Induced Peripheral Neuropathy (CIPN) pain for a minimum of 3 months after completing chemotherapy.
- Patients reporting a distressing or uncomfortable neuropathic symptom (such as pain or tingling) with an average score in the last 24 hours of ≥5 on a scale of 0-10 with 0 being none, according to the Numeric Rating Scale for pain.
- Aged 18 years or over at study entry.
- Patient's Oncology team agrees to their taking part in the study.
- Patients are able to provide written informed consent to participation in the study after explanation of the study protocol.
- In the opinion of the investigator, the patient is able to complete the various assessments.
- Neuropathy must be confined to the distal extremities (distal to elbows and/or knees).
- Pre-existing or history of peripheral neuropathy due to any cause other than chemotherapy (diabetes, alcohol, toxin, hereditary, etc.).
- Patients with any contraindication to the use of topical therapy or menthol.
- Neurological conditions which may influence findings (such as Multiple Sclerosis or residual signs/symptoms from a previous stroke).
- Skin conditions which prevent assessment of the relevant areas affected by peripheral neuropathy.
- Suffering from significant psychiatric illness, which would hinder their completion of the study in the opinion of the investigator.
- General medical condition is unstable or rapidly deteriorating, such that they are unlikely to be able to contribute to the study.
- In the opinion of the Research Team or their usual medical team, would be unable to complete the study protocol for any other reason.
- Current treatment of ≤ 30 days duration with topical lidocaine patch/gel or anticonvulsants, tricyclic antidepressants, MAO inhibitor, or other neuropathic pain medication agents such as carbamazepine, phenytoin, valproic acid, gabapentin/pregabalin, lamotrigine or amifostine. (If on the same dose of any of these medications for >31 days, patients will be asked to continue these for the duration of the study. Analgesic agents such as acetaminophen, nonsteroidal anti-inflammatory agents, or opioids, are allowed if on the same doses for >31 days).
- Application of capsaicin cream or patch (to the limb extremities) currently or within the last 30 days (as this would interfere with application of the menthol gel and potentially study outcome).
- Patients with significant pain other than CIPN (ie pain worse than the CIPN).
- Other medical conditions, which in the opinion of the treating physician/allied health professional would make this protocol unreasonably hazardous for the patient.
- Participants previously randomised into this study.
- Participants not prepared to stop using any other physical activity meter.
- Co-enrolment in any other pain treatment studies.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04276727
|Western General Hospital|
|Edinburgh, United Kingdom, EH4 2XR|
|Western General Hospital|
|Edinburgh, United Kingdom, EH4 2XU|
|Responsible Party:||University of Edinburgh|
|Other Study ID Numbers:||
|First Posted:||February 19, 2020 Key Record Dates|
|Last Update Posted:||September 14, 2022|
|Last Verified:||September 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Plan Description:||Anyone interested in secondary analysis of the data should contact the Chief Investigator in the first instance.|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Peripheral Nervous System Diseases
Nervous System Diseases